CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Optimi Health Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Optimi Health Corp
40440 THUNDERBIRD RIDGE B1831
Phone: (604) 377-0403p:604 377-0403 VANCOUVER, BC  V0N 1T0  Canada Ticker: OPTIOPTI
Business Summary
Optimi Health Corp. is a commercial-stage pharmaceutical company. The Company focuses on manufacturing and distributing good manufacturing practices (GMP) grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the Company produces validated Methylenedioxymethamphetamine hydrochloride (MDMA) and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. It supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program. With its vertically integrated approach, the Company owns and operates two purpose-built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20259/30/2025YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board John J.Wilson 37 5/1/2020 5/1/2020
Chief Executive Officer, Chief Marketing Officer and Director DaneStevens 37 10/21/2024 5/1/2020
Interim Chief Financial Officer, Director JacobSafarik 38 1/1/2025 5/1/2020
Chief Operating Officer, Director BryanSafarik 40 5/1/2020 5/1/2020
Independent Director JasonMosberian 39 12/18/2025 12/18/2025

Business Names
Business Name
8BN
OPTI

General Information
Number of Employees: 9 (As of 9/30/2021)
Outstanding Shares: 3,225,881 (As of 5/20/2026)
Stock Exchange: CNQ


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, May 30, 2026